reportcap6
About
Effectiveness against cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors and not to be able to chemotherapeutic agents throughout cancers of the breast cellular material.
Effectiveness against cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors and not to be able to chemotherapeutic agents throughout cancers of the breast cellular material.